Cellectis (Paris:ALCLS) plant sciences, the plant genome engineering company and subsidiary of Cellectis (Alternext: ALCLS), announces today the signature of a research and commercial agreement with SESVanderHave, a world leader in the sugar beet seed industry, on the use of Cellectis technologies in sugar beet.
The agreement aims at developing commercial varieties for the sugar beet seed market using new breeding techniques and targeted genetic modifications. Cellectis plant sciences will provide SESVanderHave with custom-designed meganucleases for the Sugar Beet genome, to expedite the development of new targeted traits in sugar beet.
" We believe SESVanderHave is the ideal partner to bring innovative sugar beet products to the market to address the needs of the sugar industry and the sugar beet farmers. This partnership is a new step in the implementation of our technologies " said Luc Mathis, CEO of Cellectis plant sciences.
" SESVanderHave is very enthusiast about the agreement ", said SESVanderHave CEO Rob Van Tetering. " As the innovative leader in the sugar beet seed industry, SESVanderHave is continuously seeking for new opportunities to improve its sugar beets with the objective of supplying more competitive varieties to the farmers and the sugar industry in all markets. The agreement with Cellectis will help us in finding innovative solutions for the industry in the near future ".
Financial terms of the agreement have not been disclosed.
About Cellectis plant sciences
Established in March 2010, Cellectis plant sciences is a subsidiary of Cellectis dedicated to the applications of meganucleases in plants. Its main mission is to increase and accelerate usage of Cellectis' proprietary technology in agricultural biology, broaden the company's platform to attract new and expanded licensing opportunities and explore the development of proprietary traits for selected applications. Cellectis plant sciences is located in Saint Paul, Minnesota, USA. Professor Daniel Voytas, Chief Scientific Officer of Cellectis plant sciences, is also Director of the University of Minnesota Center for Genome Engineering.
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.